ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Maruf A. Razzuk
Harold C. Urschel, Jr.
John E. Albers
James A. Martin
Donald L. Paulson
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Razzuk, M. A.
Right arrow Articles by Paulson, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Razzuk, M. A.
Right arrow Articles by Paulson, D. L.

Ann Thorac Surg 1976;21:540-545
© 1976 The Society of Thoracic Surgeons


Articles

Pulmonary Giant Cell Carcinoma

Maruf A. Razzuk, M.D.*, Harold C. Urschel, Jr., M.D., John E. Albers, M.D., James A. Martin, Ph.D., Donald L. Paulson, M.D.

Departments of Thoracic Surgery and Pathology, Baylor University Medical Center, Dallas, TX

* Address reprint requests to Dr. Razzuk, Baylor Medical Plaza, 1201 Barnett Tower, 3600 Gaston Ave, Dallas, TX 75246

Pulmonary giant cell carcinoma is one of the most highly malignant neoplasms of the lung. Eighteen patients with this tumor are presented. Histologically the neoplasm is composed of a preponderance of multinucleated giant cells, round cells, and spindle cells. Some of the most differentiated tumors show adenocarcinomatous foci and ultrastructural features of secretory epithelium, favoring its classification as a variant of pulmonary adenocarcinoma. The giant cells of this neoplasm can be differentiated from those encountered in undifferentiated large cell carcinoma and epidermoid carcinoma by the abundant cytoplasm, the presence of more nuclei and nucleoli, and the significant degree of phagocytosis. The clinical picture and roentgenographic findings present no pathognomonic features.

Complete pretreatment assessment and staging by means of mediastinoscopy should be done as in any case of bronchogenic carcinoma, and therapy should be based on the extent and stage of the disease. The results of treatment for this tumor, regardless of the form of therapy, remain unfavorable because of the high incidence of local recurrence and early metastasis. The average survival following treatment is about 5.5 months. In this series there were only 2 patients who survived beyond 5 years.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1976 by The Society of Thoracic Surgeons.